The average one-year price target for Roivant Sciences (NasdaqGS:ROIV) has been revised to $32.44 / share. This is an ...

Greenlight Capital's David Einhorn has been vocal about his concerns around artificial intelligence driving overvaluation in ...

Pulmovant, a Roivant Sciences subsidiary, has completed enrollment in the Phase 2 PHocus trial of mosliciguat for pulmonary hypertension associated with interstitial lung disease. The PHocus study is ...

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising low-cost stocks to buy now. On 10, Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy rating.

Gilead Sciences Inc (NASDAQ:GILD) stock is up 5.7%, hitting a record high of $155.56 at last glance, after the biopharmaceutical company announced a top- and bottom-line win for the fourth quarter.

Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.

Analysts' ratings for Roivant Sciences (NASDAQ:ROIV) over the last quarter vary from bullish to bearish, as provided by 4 analysts. Summarizing their recent assessments, the table below illustrates ...

Roivant Sciences stock: recent performance snapshot Roivant Sciences (ROIV) has drawn fresh attention after a strong recent run, with the share price at $25.82 and positive returns over the past week, ...